1	Combination low dose sulphonylurea and DPP4
2	inhibitor have potent glucose lowering effect
3	through augmentation of beta cell function
4	without increase in hypoglycaemia: a
5	randomised crossover study.
6	Cordiner RLM <sup>1</sup> , Bedair K <sup>1</sup> , Mari A <sup>2</sup> , Pearson ER <sup>1</sup>
7	<sup>1</sup> Division of Population, Health and Genomics, Ninewells Hospital and Medical School, University of
8	Dundee, United Kingdom
9	<sup>2</sup> Institute of Neuroscience, National Research Council, University of Padua, Italy
10	Corresponding Author
11	Professor Ewan Pearson
12	Professor of Diabetic Medicine
13	Head of Division, Division of Population, Health, and Genomics
14	Ninewells Hospital and Medical School
15	University of Dundee
16	DD1 9SY
17	Email: <u>e.z.pearson@dundee.ac.uk</u>
18	Telephone: +44 1382 383 387
19	ORCHID ID Professor Pearson: 0000-0001-9237-8585
20	ORCHID ID Dr Ruth Cordiner: 0000-0002-3022-2451
21	Word Count: 4003
22	Tweet: Cordiner et al establish that combination of low dose sulphonylurea (20mg Gliclazide) and
23	DPP4i have potent glucose lowering effect through augmentation of beta-cell function without
24	increase in hypoglycaemia. @CordinerRuth @ezpearson @UoDMedicine

#### 25 ClinicalTrials.gov: NCT04192292

## 26 Abstract

#### 27 Aims/Hypothesis.

It is important to address our use of cheaper generic therapies as the global prevalence of type 2 diabetes (T2DM) will surpass 600 million by 2035. Negative aspects of SU may be avoided by their use at low dose. We have previously shown that 20mg standard release gliclazide reduces plasma glucose through augmentation of the classical incretin effect, increased beta-cell glucose sensitivity and late-phase incretin potentiation. We hypothesised that there would be potential synergy between low dose SU when given in combination with a DPP4i, without increased hypoglycaemia risk, and aimed to assess this in a randomised clinical trial.

#### 35 Methods

36 30 participants with T2DM (HbA1c <64 mmol/mol) treated with diet or metformin monotherapy

37 were recruited to a single-centre, open-label, randomised crossover study. Participants completed

four, 14-day study periods in a random order: control, gliclazide 20mg once daily (SU), sitagliptin

39 100mg (DPP4i), or combination (SUDPP4i). A 2-hour mixed meal tolerance test was conducted at the

40 end of each block. Beta-cell function was assessed by modelling. The primary outcome was the

41 effect of treatment on beta-cell glucose sensitivity. Secondary end points included frequency of

42 blood glucose <3mmol/l on continuous glucose monitoring, sub analysis by genotype (KNCJ11 E23K),

43 and analysis by gender and body mass index.

#### 44 Results

45 Linear mixed model estimates showed a potent additive, glucose lowering effect of low dose SU

46 combination with DPP4. Mean glucose AUC (mean 95% CI) (mmol/I) was: Control 11.5 (10.7 – 12.3),

47 DPP4i 10.2 (9.4 – 11.1), SU 9.7 (8.9 – 10.5), SUDPP4i 8.7 (7.9 – 9.5) (*p* < 0.001). Beta-cell glucose

48 sensitivity (pmol min<sup>-1</sup> m<sup>-2</sup>mM<sup>-1</sup>) mirrored this additive effect: Control 71.5 (51.1 – 91.9), DPP4i 75.9

49 (55.7 – 96.0), SU 86.3 (66.1 – 106.4), SUDPP4i 94.1 (73.9 – 114.3) (p = 0.04). Glucose time in range

50 <3mmol/l on CGM (%) was unaffected: Control 1 (2-4), DPP4i 2 (3-6), SU 1 (0-4), SUDPP4i 3 (2 – 7) (p

51 = 0.65). The increase in glucose sensitivity with sulphonylurea treatment was seen in men not

52 women.

#### 53 Conclusions

54 Combination low dose gliclazide with a DPP4i has potent glucose lowering effect through 55 augmentation of beta cell function. Glucose reduction was achieved at gliclazide concentrations far 56 below those achieved with standard therapeutic doses. A double-blind randomised controlled trial

- 57 is merited to formalise efficacy and safety of this combination, which may avoid negative aspects of
- 58 SU and provide pharmacoeconomic benefit in diabetes care.

# 60 Research in Context

- 61 What is already known about this subject?
- 62 Previous isoglycaemic clamp studies in low dose sulphonylureas established that 20mg of gliclazide
- augments the classical incretin effect, increases glucose sensitivity by 50% and late phase incretin
- 64 potentiation.

## 65 What is the key question?

- 66 What is the effect of low dose sulphonylureas as monotherapy or in combination with a DPP4i on
- 67 parameters of beta cell function following a mixed meal?
- 68 What are the new findings?
- 69 Low dose sulphonylureas have potent glucose lowering potential which is further enhanced by the
- 70 addition of a DPP4i, without increasing hypoglycaemia.
- 71 Modelling of beta cell function demonstrates that low dose sulphonylureas heighten the beta cell
- 72 dose response which is further augmented by the presence of a DPP4i.
- 73 Phenotypic differences in response are noted, with male participants showing additional effect of
- 74 glucose sensitivity in response to sulphonylureas. This effect is not seen in women.
- 75 Gliclazide standard release at 20mg produces a similar pharmacokinetic profile during mixed meal
- 76 tolerance test to 30mg of modified release gliclazide.

## 77 How might this impact on clinical practice in the foreseeable future?

- 78 These results suggest that it is possible to modernise the use of two cheap, effective second-line
- reatments of type 2 diabetes mellitus through future production of a combined preparation of low
- 80 dose gliclazide and a DPP4i. This combination has real potential as a safe, efficacious treatment
- 81 which could bring pharmacoeconomic benefit to low- and middle-income countries worldwide.

# <sup>83</sup> Introduction (Current 4003).

84 Sulphonylureas (SU) have been utilised in the treatment of type 2 diabetes mellitus (T2DM) for over 85 70 years (1). However, their use has declined due to their associations with hypoglycaemia, weight 86 gain, limited durability, and their lack of positive cardiovascular outcome data in comparison with 87 newer agents. Currently, international guidelines recommend the use of SU "if cost is an issue" (2). 88 However, the cost of diabetes care is escalating; the global prevalence of T2DM is predicted to 89 increase from 382 million people to 592 million by 2035, which includes 69% increase in prevalence 90 in developing countries and a 20% increase in developed countries (3, 4). The predicted absolute 91 global economic burden of diabetes care will increase from \$1.3 trillion US Dollars (95% confidence 92 interval 1.3 - 1.3 in 2015 to \$2.2 trillion (2.2 - 2.3) in 2030, which translates to an increase in costs 93 as a share of the global GDP from 1.8% (1.7 - 1.9) in 2015 to a maximum of 2.2% (2.1 - 2.2) (5). This 94 increase in per capita cost therefore poses a global emergency to control cost. A systematic review 95 indicated that the economic burden of diabetes most directly affects patients in low- and middle-96 income countries (LMIC), with the magnitude of cost differing considerably between countries (6). 97 Therefore, there is pharmacoeconomic need to provide cost-effective diabetes care, including how 98 we modernise our use of our cheaper generic therapies such as SU and DPP4 inhibitors (DPP4i). 99 Studies in neonatal diabetes mellitus (NDM) have provided insight into the beta-cell response of SU. 100 Studies in patients with NDM due to activating mutations in KCNJ11, found that these patients were 101 able to effectively switch from insulin to high dose SU, with resulting tight glycaemic control whilst 102 avoiding hypoglycaemia. Patients with NDM have no insulin response to intravenous glucose but 103 have a significantly increased insulin response to oral glucose or mixed meal stimulus following SU 104 initiation, suggesting augmentation of the incretin effect (7, 8). In addition, a supra-additive effect of 105 SU in combination with high concentrations of intravenous GIP has also been shown in HNF1A-106 maturity onset diabetes of the young (HNF1A MODY) (9) and in T2DM treated with standard dose 107 glipizide (10). Our previous work has shown that low dose SU augment the incretin effect (11). Using 108 isoglycaemic clamps in patients with T2DM treated with diet or metformin monotherapy, we 109 demonstrated that a 20mg dose of gliclazide reduced mean glucose AUC during oral glucose 110 tolerance test from 12.0 to 10.8 mmol/l (p=0.0006), augmented the incretin effect from 35.5 to 55% 111 (p=0.04), and increased glucose sensitivity by 50% (p=0.01) and enhanced late phase incretin

112 potentiation (*p*=0.04).

Given that we have uncovered a novel mechanism of SU at low dose that results in glucose regulated insulin secretion, in part mediated by the incretin effect, we hypothesised that DPP4i, which increase endogenous incretins, would be a potent drug to combine with low dose SU. We aimed to explore

- 116 the efficacy of low dose SU and endogenous incretins, as monotherapy, and in combination with a
- 117 DPP4i on parameters of beta cell function utilising multiple mixed meal tolerance tests (MMT), beta
- 118 cell modelling and continuous glucose monitoring (CGM).

# 119 Methods

#### 120 Recruitment

- 121 30 participants were recruited with physician diagnosed T2DM treated with diet or metformin
- 122 monotherapy, HbA1c <64 mmol/mol, aged ≥ 40 and ≤ 80 years and with renal and hepatic function
- 123 in the biochemical reference range from local laboratories. To avoid heterogeneity within the
- 124 cohort, only White British participants were recruited. All participants had capacity to express
- 125 informed, written consent. Participants not meeting inclusion criteria were excluded. Patients who
- 126 were pregnant, lactating or planning to conceive within the study period were ineligible. Patients
- 127 participating or who were recruited in a clinical study within the preceding 30 days were also
- 128 ineligible.

#### 129 Study Design

- 130 We undertook a single-site, open label, randomised crossover study involving MMT (Figure 1). The
- 131 study was approved by The East of Scotland Research Ethics Committee (REC 18/ES/0092) and
- registered with ClinicalTrials.gov (NCT04192292). All research was conducted in accordance with the
- 133 Declaration of Helsinki, and informed written consent was obtained for all participants prior to study
- inclusion.
- 135 Study visits took place at The Clinical Research Centre, Ninewells Hospital and Medical School. The
- 136 study involved four intervention blocks, each of 14-days duration, to assess response following
- 137 different combination of low dose SU or DPP4i: no intervention (no change to standard care), low
- dose SU (20mg gliclazide once daily), DPP4i (100mg sitagliptin once daily), low dose SU + DPP4i
- 139 (20mg gliclazide + 100mg sitagliptin once daily).
- 140 Participants attended the research centre on 6 separate visits. A screening visits confirmed eligibility

and obtained informed written consent. The second visit provided education regarding study drugs,

- self-monitoring of blood glucose, and hypoglycaemia. The other four visits were performed at the
- 143 end of each block.
- 144 Participants underwent a 2-hour MMT at the end of each block. Participants were fasted for 8-hours
- 145 prior to intervention and all regular medications, including metformin, were withheld until the end
- 146 of the test. On arrival to the centre, a single intravenous (IV) cannula was inserted into the
- 147 participant's arm for blood sampling. For MMT involving study drug, participants took the study drug

- 148 on arrival at the research centre. After 60 minutes, a standard liquid meal (Fortisip Compact,
- 149 Nutricia, NL) was given. Blood samples for insulin, C-peptide and glucose were taken at 7 defined
- time points: 0, 15, 30, 35, 60, 90 and 120 minutes. A single sample for Total GLP-1, GIP and glucagon
- 151 concentrations was taken at time 0. Plasma concentrations of gliclazide were sampled at time 0, 60,
- and 120 minutes in all participants (n=30); 9 participants were consented to complete a prolonged
- 153 MMT for further sampling at 4, 8 and 24 hours for gliclazide pharmacokinetic profiling. The end of
- 154 study was determined as last patient last visit.

## 155 Materials

#### 156 Study Drugs

- 157 Gliclazide 40mg tablets were sourced from Alliance Pharmaceuticals (UK) and halved by Tayside
- 158 Clinical Trials Pharmacy. The DPP4i was sitagliptin in the form of Januvia 100mg tablets (Merck Sharp
- and Dohme Ltd, UK). A 100mg once daily dosing schedule was chosen as pharmacokinetic studies in
- 160 healthy individuals showed a more consistent DPP4 inhibition profile over a 24-hour period. In
- 161 comparison, a 50mg dose only provided 12-hours of consistent DPP4 inhibition (12).

#### 162 Liquid Meal

- 163 The liquid meal comprised 160ml of Fortisip Compact, the nutritional content for the given volume
- 164 was: 184 kilocalories, protein 15.36 grams, carbohydrate 47.52 grams, fat 14.88 grams, nil fibre.

#### 165 Continuous Glucose Monitors

166 The Freestyle Libre Pro Flash Continuous Glucose Monitoring System was used throughout study167 (Abbott).

#### 168 Blood Collection

- 169 All blood collection was performed utilising BD Vacutainer systems (Becton, Dickinson and Company,
- 170 NJ, USA). Samples were iced following collection and centrifuged immediately in accordance with
- 171 recommended guidance from receiving laboratories.

#### 172 Laboratory Analyses

- 173 Insulin and C-Peptide
- 174 Analysis of insulin and C-peptide was performed by Clinical Chemistry, Royal Devon, and Exeter
- 175 Hospital 602 modules Cobas 8000 automated platform using sandwich chemiluminescence
- immunoassay (Elecsys insulin, Belgium)

#### 177 Glucose

- 178 Glucose analysis was performed by NHS Tayside Blood Sciences at Ninewells Hospital utilising
- 179 Siemens ADVIA Chemistry, Glucose Hexokinase\_3 Concentrated Reagents (UK).

#### 180 Glucagon

- 181 Glucagon analysis was performed by the Immunoassay Core Biomarker Laboratory, University of
- 182 Dundee, utilising EMD Millipore glucagon radioimmunoassay kit (Merck, Billerica, MA, USA).

#### 183 Incretins

- 184 Total GLP-1 and GIP analyses were performed by the Immunoassay Core Biomarker Laboratory,
- 185 University of Dundee, utilising MSD metabolic assay Total GLP-1 and GIP assay (MSD, MD, USA).

#### 186 Gliclazide

- 187 Gliclazide analysis was performed by the Biomarker and Drug Analysis Core Facility, University of
- 188 Dundee utilising a uniquely developed gliclazide quantification method in human plasma by liquid
- 189 chromatography separation, and tandem mass spectrometry analysis.

## 190 Data and Statistical Analyses

### 191 Study Outcomes

- 192 The statistical analysis is included in Supplementary Information. The primary outcome was the
- change in glucose sensitivity at MMT. Secondary outcomes included: the effect of treatment on
- 194 parameters of beta-cell function, biochemical parameters (glucose, insulin, c-peptide, and incretin
- 195 hormones) and the pharmacokinetic profile of low dose gliclazide. The frequency of blood sugar
- 196 levels <3mmol/l on CGM, and the effect of KCNJ11 (E23K) genotype and gender on change in glucose
- 197 sensitivity with drug treatment were also evaluated.

#### 198 Randomisation

- 199 Participants were randomised to intervention order using an unblinded web-based randomisation
- software (<u>www.randomisation.com</u>). A copy of the randomisation plan was stored in the research
- 201 centre, Tayside Clinical Trials Pharmacy, and the site file.

#### 202 Power

- 203 Based on previous data in T2DM, the standard deviation of the difference in AUC glucose between
- placebo and vildagliptin treatment was 125mmol/l over 240 minutes (13). With 30 patients, the
- study would have 80% power (p=0.05) to detect a difference of 1/3 of that seen with vildagliptin
- alone compared with placebo. Similarly, the power would be enough to detect approximately 50% of
- 207 the difference in AUC<sub>INSULIN</sub>:AUC<sub>GLUCOSE</sub> ratio seen comparing vildagliptin and placebo.

#### 208 Modelling

- 209 Two models were developed, a linear mixed effects model and a generalised additive model, both of
- which considered the hierarchical nature of the study design of three levels: treatment (n=4),
- 211 participant (n=30) and time within the MMT (n=7 time points per MMT). Participants were
- randomised to block order and the MMT took place on either day 14, 28, 42 or 56 from the start of
- 213 study.
- 214 Linear Mixed Model with Random Effect
- For the primary outcome a linear mixed effects model was applied (14) with glucose sensitivity as
- the dependent variable. Synergy was evaluated via post-hoc pairwise comparisons between
- treatments. In this model, treatment intervention was considered a fixed effect, as was time within
- the MMT. Inter-subject variability, block randomisation and day of MMT were considered as random
- effects. Finally, 2 accounted for all other random effects. All assumptions of linear mixed effect
- 220 model residuals were checked for deviation from homoscedasticity or normality.

#### 221 Generalised Additive Model

- As the time course of the insulin, c-peptide, incretin, and glucagon response across the MMT were
- 223 considered as non-linear parameters, a generalised additive model was developed (15). In this
- analysis, "Treatment" was considered as a fixed effect whereas "Time" was considered as a fixed,
- 225 non-linear effect. The model applied smoothing parameters to random effects of inter-subject
- variation, block randomisation and day. The model fit was checked using the "mgcv" package in R
- 227 (15).

#### 228 Parameters of Beta Cell Modelling

- 229 Beta cell function was assessed using a previously described model (16, 17)(18), designed to analyse
- 230 the MMT tests. The model describes the relationship between insulin secretion and glucose
- 231 concentration by means of a dose-response function relating the two variables and an early
- secretion component. The dose-response is characterised by its average slope, termed glucose
- sensitivity, and early secretion by a parameter denoted as rate sensitivity, a marker of early phase
- insulin release. The dose response function is modulated by a time-varying potentiation factor,
- 235 which accounts for effects of sustained hyperglycaemia and incretins. The potentiation factor
- excursion was calculated as the ration between the values at the end of the 2-h OGTT and at
- 237 baseline.

#### 238 Data Presentation

Model results are presented in tables of estimates (mean (95% confidence intervals)), standard
 error, test statistic and *P*-value. A significant *P*-value result provided in the "*Control*" arm represents

- that the intercept is significantly different to 0. *P*-values for treatment interventions demonstrate
- 242 statistical significance versus control.

#### 243 Statistical Software

- 244 Data were managed utilising Microsoft Excel as part of Microsoft Office 365 Pro Plus Version 1908
- 245 (Build 11929.20708). Statistical analysis and graphical presentation were performed in R (19).

## 246 **Results**

#### 247 Baseline Characteristics

- 248 Study recruitment ran from September 2019 to September 2020. All study activity was paused due
- to COVID-19 pandemic between March and August 2020. Two participants withdrew consent for
- study immediately after screening in March 2020 due to the COVID-19 pandemic; these participants
- 251 were replaced. One participant withdrew prior to last MMT due to circumstances unrelated to study;
- data until point of withdrawal were retained as per study consent.
- 253 Baseline characteristics of the study cohort (n=30) were representative of SU users in the Tayside
- region (Table 1). In a sub-analysis by gender, male participants had lower BMI (median (LQ, UQ))
- 255 (Male 30.5 (25, 33) vs Female 39 (31, 41) kg/m<sup>2</sup> (p<0.001)) and were older (Male 67.5 (64, 71) vs
- Female 59 (54, 66) years, (*p* = 0.02). The most common concomitant medications were metformin
- 257 (n=27), statins (n=26), proton pump inhibitors (n=13) and selective serotonin reuptake inhibitors
- 258 (11).
- Adverse events included one episodes of symptomatic hypoglycaemia (BM 3.3 mmol/l) which
- 260 occurred on DPP4-inhibitor monotherapy. There were 14 occurrences of detachment of CGM
- 261 sensors which were documented as adverse events. Sensors were replaced on the next working day
- following report to the study team.

#### 263 Primary Outcome: change in glucose sensitivity with treatment.

Linear mixed model parameters of beta cell function are summarised in Table 2. The plot of glucose

- sensitivity suggests additive effect of treatment (Figure 2A). However, the linear mixed model
- estimates only show difference in glucose sensitivity with SUDPP4i compared to baseline (*p*=0.04)
- 267 (Table 2).
- 268 Figure 3 shows the model-determined relationship between insulin secretion and glucose
- 269 concentration in each of the four intervention groups. A progressive increase in slope is observed
- 270 across the treatments, representative of the corresponding increase in glucose sensitivity. A left shift
- is noted in favour of combination treatment in both glucose sensitivity and insulin secretion at

- 272 8mmol/l (Figure 2B), demonstrating augmentation of beta cell function at lower glucose
- 273 concentrations.

#### 274 Secondary Outcomes

- 275 Rate sensitivity, which is a marker of early insulin release, was augmented by both gliclazide
- interventions (Figure 2C, Table 2). This is expected, as gliclazide is a secretagogue influencing early
- insulin secretion. Predictably, this effect was not further augmented by the combination with DPP4i.
- 278 There was no difference in potentiation factor ratio (Table 2). The trend towards an increase in
- 279 SUDDP4i suggests that had the MMT been prolonged (Figure 2D), difference may have been
- 280 observed in late phase potentiation as in our previous study on the incretin effect, which lasted four
- 281 hours (11).

#### 282 Glucose

- 283 The mean fasting and mean glucose AUC were reduced in all treatment groups compared with
- control (Figure 4). Linear mixed modelling outcomes showed additive effect in terms of difference
- between estimates of both DPP4i and SU groups versus SUDPP4i (Table 3). SUDPP4i reduced mean
- 286 glucose AUC compared with both treatments as monotherapy.

#### 287 Insulin and C-Peptide

- 288 The generalised additive model estimates showed no effect of treatment on either incremental AUC
- 289 (iAUC) insulin or C-peptide (Table 2). However, when interpreted in context of significant glucose
- 290 reduction, this would suggest an overall improvement in beta cell function (Table 3).

#### 291 Incretins

- As our previous work found that low dose gliclazide had no impact on dynamic endogenous incretin
- 293 or glucagon secretion (11), only fasting measurements were performed. Generalised additive model
- 294 estimates showed that SU reduced fasting GLP-1, GIP, and glucagon concentrations (Supplementary
- 295 Information Table 1).

#### 296 Gliclazide Pharmacokinetics

- 297 Study drugs were administered 60 minutes prior to the start of the MMT. Mean gliclazide
- concentrations (mean (SD)) (ng/ml) were SU 662 (408), SUDPP4i 603 (355) respectively (p = 0.31)
- and maximum concentrations were 749 (433) and 645 (397) ng/ml (p=0.01) in the SU and SUDPP4i
- 300 meal tests, respectively. Combination treatment did not affect the 24-hour profile of gliclazide:
- 301 mean gliclazide AUC 660 (328) and 535 (223) ng/ml (p=0.1), maximum concentration 770 (328) and
- 302 793 (413) (p=0.8). Trough concentrations of gliclazide were 370 (183) and 343 (183) ng/ml in the SU
- 303 and combination groups, respectively.

#### 304 Continuous Glucose Monitoring

Blood glucose <3mmol/l was considered as biochemically significant hypoglycaemia in line with the</li>
European and American joint position statement (21). Linear mixed effects modelling of time in
range (TIR) <3mmol/l on CGM (%) was unaffected: Control 1 (2-4), DPP4i 2 (3-6), SU 1 (0-4) (p=0.64).</li>
Only treatments involving SU increased TIR 3-10mmol/l (%) versus control: Control 67.4 (56.6 –
78.2), DPP4i 64.5 (45.6 – 83.74), SU 71.83 (52.59 – 17.25), SUDPP4i 68.4 (66.16 – 85.83) (p<0.001 SU</li>
& SUDPP4i versus control).

#### 311 Effect of *KCNJ11* (E23K) Genotype

The study cohort included 12 EE, 5 KK and 12 EK heterozygotes, which is slightly higher than the 34 – 48% minor allele frequency reported for Caucasian populations (22). Linear mixed model estimates showed additive effect of treatment on glucose parameters in EE homozygotes only (Supplementary Information Table 2) and fasting insulin and C-peptide in those carrying the K-allele. Plots of the glucose sensitivity suggest a steeper slope in K-allele carriers (Figure 5); however, the linear mixed model estimates were not statistically significant.

## 318 Effect of Gender

- As previous literature had suggested differing response to SU by sex and BMI (23), the model was
- 320 adjusted for this interaction. Sub analysis of glucose sensitivity and the dose response revealed a
- 321 potent additive effect in male participants, which was not observed in female participants (Figure 6).
- 322 Linear mixed modelling estimates suggest that women respond better to DPP4is, which has not been
- 323 previously documented, with no difference in glucose lowering effect between DPP4i and SU. In
- 324 contrast, men showed a greater response to interventions involving SU, including between SU and
- 325 combination treatment (Supplementary Information Table 3).

## 326 Discussion

- 327 The study describes the effect of low dose SU as monotherapy, or in combination with a DPP4i on
- 328 parameters of beta-cell function in response to a standardised meal with four different
- 329 interventions: control, 100mg sitagliptin, 20mg gliclazide or both. Our results show that combination
- 330 treatment with SU and DPP4i enhanced glucose control and beta-cell function, without
- 331 hypoglycaemia on CGM which supports that this combination could have potential use as an
- 332 effective, low-cost treatment. However, the observed increase in glucose sensitivity with
- combination treatment was not greater than the sum of the monotherapy responses.

## Low dose sulphonylureas are potent glucose lowering agents whilst avoiding

## 335 hypoglycaemia.

336 In this study, we show that 20mg of gliclazide has potent glucose lowering potential which is further 337 enhanced by the addition of a DPP4i whilst avoiding hypoglycaemia. A 2.8 (0.305) mmol/l (mean 338 (SEM)) reduction in mean glucose from AUC was observed with combination treatment versus 339 control. Strikingly, 20mg of gliclazide as monotherapy was as potent as 100mg sitagliptin (mean 340 glucose reduction 1.8 mmol/l (0.3), 1.3 (0.3) mmol/l p=0.27 gliclazide vs sitagliptin respectively). A 341 meta-analysis of studies combining standard dose SU with DPP4i have shown a 50% increased risk in 342 hypoglycaemia in the first 6 months of treatment (24). We used 20mg gliclazide in this study, which 343 showed no difference in the frequency of hypoglycaemic events between treatments. 344 We propose mechanistically that low dose SU do not cause hypoglycaemia due to their effect on the 345 K<sub>ATP</sub> channel open state, similar to their mechanism observed in *KCNJ11* neonatal diabetes mellitus 346 (NDM) (25). In KCNJ11 NDM, high dose glibenclamide is required to promote insulin secretion and

successful transition off insulin (7). Even at these high doses the mutant K channels do not shut
 completely, resulting in a beta-cell resting membrane potential that is sub-threshold for insulin

349 release but primed for other stimuli such as incretins. In T2DM, where there are only minor defects

350 in K<sub>ATP</sub> channel function, normal doses of SU fully close the K<sub>ATP</sub> channels resulting in insulin secretion

despite normal or low glucose. Our findings suggest that a very low dose of SU in T2DM achieves a

similar partial closure of the K<sub>ATP</sub> channels as seen for high dose SU in NDM, working primarily to

prime the beta-cell to other secretagogues such as the incretins or amino acids, resulting in glucose

regulated insulin secretion and no insulin secretion in the presence of normal or low blood glucose.

Therefore, it could be possible to achieve the glycaemic benefits of SU, whilst minimising negative attributes.

# Combination low dose sulphonylurea and DPP4i heighten parameters of betacell function with additional effect on glucose lowering.

Modelling of beta cell function showed progressive augmentation of the slope of the dose-response (glucose sensitivity) in favour of SUDPP4i, however, although there was clear additive effect, there was no evident synergy as hypothesised. The relationship of the dose-response is presented in Figure 3; there are two parameters characterising this relationship. The first is glucose sensitivity, and the second is insulin secretion at fixed glucose concentration, which is equivalent to an

364 intercept. It may be that the left shift in the dose-response may at least in part be independent of

365 glucose sensitivity, however in this study significant additive effect is also seen in this parameter. It

366 can be postulated that SU in this instance are enhancing insulin section, but maintaining glucose

- 367 dependence, thus avoiding hypoglycaemia, as supported by our CGM findings. The impact of
- 368 gliclazide on glucose sensitivity has been previously suggested in rat models (26, 27) and in healthy
- 369 human participants (28), albeit at high dose.

#### 370 Gliclazide pharmacokinetics

- 371 This study explored the 24-hour plasma concentration profile of 20mg standard release gliclazide,
- observing trough concentrations of ~370 ng/ml, mean plasma concentrations of 500 600 ng/ml and
- 373 peak of 908 ng/ml. For comparison, an 80mg dose of gliclazide generates peak plasma
- 374 concentrations of between 3000 5000ng/ml (29). Interestingly the plasma concentrations
- observed in this study are only a little lower than those documented for 30mg gliclazide MR: trough
- 472, mean 800 and maximum concentrations of 1100 ng/ml, respectively. A multi-centre double-
- 377 blind RCT compared the efficacy and safety of gliclazide MR vs glimepiride, in a cohort which
- included those at higher risk of SH (>65 years and renal impairment). Both groups achieved HbA1c
- reduction of 1.0% with fewer hypoglycaemic events with gliclazide MR than glimepiride (3.7 vs 8.9%)
- 380 (30), which suggests that low dose modified release preparations may be preferential in terms safety
- 381 with similar cost and efficacy to standard release SU.

#### 382 Response by Genotype

383 In this study K allele (diabetes-risk allele) carriers showed higher fasting glucose, reduced insulin 384 secretion and beta cell function. Differences were observed in terms of plasma glucose and beta-cell 385 function in carriers of the K allele, but there was no difference in the response to treatment. Plots of 386 the dose response suggest that K-allele carriers have lower fasting insulin secretion, but in the 387 control group there was a greater slope of glucose sensitivity than EE homozygotes, similar to 388 previous literature (31). However, the difference in slopes with gliclazide treatment was more 389 pronounced in EE homozygotes suggesting that the 20mg dose may not be high enough to 390 sufficiently close the  $K_{ATP}$  channels in K allele carriers to allow the amplifying pathway to operate. 391 This is supported by a previous study which suggested that K allele carriers require higher doses of 392 SU to achieve glucose reduction, and even higher doses in KK homozygotes (32). A dose-response by 393 genotype study would be required to fully investigate this effect.

#### 394 Gender differences in response

395 It is interesting that the additive pattern of glycaemic reduction and increase of beta-cell function

- 396 with SU or in combination with a DPP4i is only seen in men, but not women. However, sub analysis
- shows the additive effect on insulin secretion at 8mmol/l glucose is preserved in women, which does
- 398 suggest effect independent of glucose sensitivity in this instance. These differences in physiological
- responses by gender mirror findings in large cohort studies (23). In an analysis of subgroups of BMI

- 400 and gender in patients (n=22,379) starting SU or TZD in the UK Clinical Practice Data Research 401 Datalink (CPRD), non-obese males (BMI <30) had a 3.3 mmol/mol better response to SU than TZD 402 (p<0.001), these findings were replicated in the ADOPT study (first-line treatment) (33) and observed 403 in the RECORD study (34). These studies support that there is a sex difference in SU response, and 404 our study provides some physiological insights into these differences. Possible explanations include 405 that the women had higher BMI, although adjusting for BMI does not remove the sex difference 406 (data not shown); or a sex difference in incretin physiology. The ADDITION-PRO study reported that 407 women have greater increased serum GLP-1 concentrations following OGTT than men, even after
- 408 adjustment for BMI (35). Further studies are warranted to further investigate this.

## 409 Limitations

- 410 The main limitation in this study is the wide variability in beta-cell response within a small cohort,
- 411 which limits power and ability to perform further sub-analysis. However, the population would
- reflect those who would merit second-line intensification in real-world medicine. This open-label
- 413 physiological study design was adopted as further proof-of-concept prior to undertaking a formal
- randomised controlled trial (RCT) The ideal study design would have been a double-blinded RCT, but
- 415 this was not feasible at this stage.
- 416 The advantage of beta-cell modelling is the ability to model static and dynamic parameters of beta-
- 417 cell function, beyond traditional measures of glucose and insulin secretion. However, as a more
- 418 complicated procedure, involving multiple parameters it may add some estimation error.

# 419 Conclusion

- 420 We have shown that low dose sulphonylureas are potent glucose lowering agents, which increase
- 421 the beta-cell dose response to glucose without increasing hypoglycaemia. This response is further
- 422 augmented in the presence of a DPP4 inhibitor, although we did not see synergy with this
- 423 combination. A formal randomised controlled trial of the efficacy and safety of a low dose
- 424 sulphonylurea in combination with a DPP4 inhibitor is warranted as a combination treatment may
- 425 allow modernisation of two cheap, effective treatments of T2DM with considerable potential for
- 426 pharmacoeconomic benefit worldwide.

# 427 Acknowledgements

- 428 The authors would like to thank the study team of The Clinical Research Centre, Ninewells Hospital
- 429 and Medical School, Dundee: H Loftus, L Cabrelli, G Wilkie, G Kiddie, D Pankhurst and C Shearer.
- 430 Thanks to T McDonald and R Nice of the Department of Clinical Chemistry, University of Exeter for
- 431 insulin and c-peptide measurements. J Burns of Ninewells Hospital and Medical School, Dundee for

- 432 measurement of glucose concentrations, J Huang and the Department of Biomarker and Drug
- 433 Analysis, University of Dundee for the development of the gliclazide mass spectrometry method and
- 434 the Immunoassay Core Biomarker Facility, University of Dundee for incretin and glucagon
- 435 measurement.

# 436 Data Availability

- 437 Some or all datasets generated and/or analysed during the current study are not publicly available
- 438 but are available from the corresponding author on reasonable request.

# 439 Funding

440 This research was funded by a New Investigator Award to ERP from Wellcome (102820/Z/13/Z).

## 441 Conflict of Interest

- 442 RLMC and KB have no conflict of interest to disclose. AM has received research grants from
- Boehringer Ingelheim and Eli Lilly and consultancy fees from Eli Lilly. ERP has received honoraria
- 444 from Sanofi and Eli Lilly.

# 445 Contribution Statement

- 446 RLMC and ERP conceived, designed and acquired study data. RLMC, KB and ERP designed the
- 447 statistical analysis plan. RLMC undertook statistical analysis with advice from KB, ERP and AM. AM
- 448 and AT conducted beta-cell modelling analysis and interpretation. RLMC and EP wrote the initial
- drafts of the manuscript, these drafts were revised for important scientific content by all authors. All
- 450 authors gave final approval of the version to be published. ERP is the guarantor of this work.

451

452

# 454 Figure Legends

- 455 Figure 1
- 456 Figure 1: Unblinded randomised crossover study design involving four different study intervention
- 457 periods, each 14 days duration. Participants completed a 2-hour mixed meal tolerance test at the
- 458 end of each study period.
- 459 Figure 2
- 460 Figure 2: a) Glucose sensitivity b) Insulin Secretion at 8mmol/l glucose c) Rate Sensitivity d)
- 461 Potentiation Factor by treatment (Mean (SEM))
- 462 Figure 3
- 463 Dose response by treatment (Mean (SEM))
- 464 Figure 4
- 465 Mean (SEM) a) Fasting Glucose b) Glucose from Mixed Meal Test
- 466 Figure 5
- 467 Dose response to treatment by KCNJ11 E23K genotype (Mean (SEM))
- 468 Figure 6
- 469 Gender Differences in Treatment Response (Mean (SEM)) a) Glucose from Mixed Meal Test
- b) Glucose Sensitivity c) Insulin Secretion at 8mmol/L Glucose
- 471
- 472

# 473 Table 1

Phase of Study	Number of Participants	Gender (M/F)	Pre-Existing Treatment (Diet/Metformin)	Age (Years)	Body Mass Index (Kg/M <sup>2</sup> )	Body Surface Area (M <sup>2</sup> )	HbA1c (mmol/mol)	Duration of Diabetes (Years)
Full Study	30	16/14	3/27	66 (57,70)	32.4 (28.40)	2.1 (1.9, 2.3)	54 (48, 62)	6.5 (4.8, 10.0)
Pharmacokinetic Phase	9	3/6	3/6	66 (64, 72)	30.7 (27, 38)	2.1 (1.7, 2.4)	50 (48, 60)	5 (5, 10.5)

474

475 Table 1: Baseline Characteristics (Median (Lower Quartile, Upper Quartile)).

476 30 Participants were analysed for the primary outcome of study. 9 Participants completed prolonged

477 mixed meal tolerance tests for 24-hour sampling for low dose gliclazide pharmacokinetic profiling.

478

# 480 Table 2

	Glucose Sensitivity (pmol min <sup>-1</sup> m <sup>2</sup> mM <sup>-1</sup> )				
Coefficient	Estimates	Standard Error	P-Value		
Control	71.5	10.2			
	(51.6 – 91.4)				
DPP4i	75.9	11.0	0.70		
	(34.3 – 117)				
SU	86.3	11.0	0.18		
	(44.7 – 128)				
SUDPP4i	94.1	11.0	0.04		
	(52.6 – 136)				
	Rate Sensitivity (pmol m <sup>2</sup> mM <sup>-1</sup> )				
Control	494	140			
	(220 – 769)				
DPP4i	611	188	0.53		
	(-32 – 1260)				
SU	914	188	0.03		
	(270 – 1556)	(270 – 1556)			
SUDPP4i	879	188	0.04		
	(234 – 1522)				
	Potentiation Factor				
Control	1.07	0.06			
	(0.95 – 1.19)				
DPP4i	1.09	0.08	0.79		
	(0.81 – 1.37)				
<b>SU</b> 1.08		0.08	0.86		
	(0.80 - 1.36)				
SUDPP4i	1.17	0.08	0.23		
	(0.89 – 1.45)				

481

482 Table 2: Linear mixed effects modelling results of parameters of beta cell function. Estimates are

483 shown as mean (95% confidence intervals). All values are rounded to 3 significant figures. *P*-values

for treatment interventions demonstrate statistical significance versus control.

484

485

# 487 Table 3

	Mean Fasting Glucose (mmol/l)			Mean Glucose from AUC (mmol/l)			
Coefficient	Estimates	Std Error	P-Value	Estimates	Std Error	P Value	
	(95% CI)			(95% CI)			
Control	8.59	0.37		11.5	0.42		
	(7.88–9.31)			(10.7 – 12.3)			
DPP4i	7.51	0.23	<0.001	10.25	0.30	<0.001	
	(7.06 – 8.68)			(8.84 – 11.7)			
SU	7.25	0.23	<0.001	9.7	0.30	<0.001	
	(6.09 - 8.42)			(8.29 – 11.1)			
SUDPP4i	6.83	0.23	<0.001	8.7	0.30	<0.001	
	(5.6 – 8)			(7.29 – 10.1)			
	Fasting Insulin (pmol/I)			Fasting C-Peptide (pmol/l)			
Contro	170	27.1		1503	118		
	(117 – 224)			(1271 – 1735)			
DPP4i	137.17	14.8	0.03	1370	62.7	0.04	
	(55.2 – 219)			(1016 – 1725)			
SU	165.46	14.8	0.76	1495	62.7	0.9	
	(83.5 – 199)			(1141 – 1620)			
SUDPP4i	182.24	15.1	0.42	1615	62.7	0.07	
	(99.6 – 265)			(1261 — 1969)			
	Incremental AUC Insulin (nmol/l/min <sup>-1</sup> )		Incremental AUC C-Peptide (nmol/l/min <sup>1</sup> )				
Contro	41.1	5.39		144	16.8		
	(30.4 – 51.7)			(111 – 177)			
DPP4i	43.0	7.56	0.71	159	19.8	0.45	
	(18.2 – 34)			(120 – 131)			
SU	42.0	7.55	0.90	151	19.8	0.72	
	(16.4 - 67.6)			(112 – 224)			
SUDPP4i	44.3	7.58	0.66	154	19.8	0.65	
	(18.7 – 70.1)			(81.2 - 226)			

488

489 Table 3: Summary of linear mixed model outcomes for glucose and generalised additive model

490 outcomes for insulin, and C-peptide from mixed meal tolerance test. Estimates are Mean (95%
 491 Confidence interval). All values are rounded to 3 significant figures. *P*-values for treatment

interventions demonstrate statistical significance versus control.

492

493

494

# 496 **References**

1. A L. Relations entre la structure moleculaire et l'activite 497 498 hypoglycamiante des aminobenzene-sulfamido-alkylthiodiazols. Archives International Physiology. 1944:174-7. 499 Introduction: Standards of Medical Care in Diabetes—2019. Diabetes 500 2. Care. 2019;42(Supplement 1). 501 3. Federation ID. International Diabetes Federation Atlas 2013. 502 Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of 4. 503 diabetes for 2010 and 2030. Diabetes Research and Clinical Practice. 504 505 2010;87(1):4-14. Bommer C, Sagalova V, Heesemann E, Manne-Goehler J, Atun R, 506 5. Bärnighausen T, et al. Global Economic Burden of Diabetes in Adults: 507 Projections From 2015 to 2030. Diabetes Care. 2018;41(5):963-70. 508 Seuring T, Archangelidi O, Suhrcke M. The Economic Costs of Type 2 509 6. 510 Diabetes: A Global Systematic Review. PharmacoEconomics. 2015;33(8):811-31. 511 7. Pearson ER, Flechtner I, Njolstad PR, Malecki MT, Flanagan SE, Larkin 512 B, et al. Switching from insulin to oral sulfonylureas in patients with diabetes 513 514 due to Kir6.2 mutations. N Engl J Med. 2006;355(5):467-77. Zung A, Glaser B, Nimri R, Zadik Z. Glibenclamide Treatment in 515 8. 516 Permanent Neonatal Diabetes Mellitus due to an Activating Mutation in Kir6.2. The Journal of Clinical Endocrinology & Metabolism. 2004;89(11):5504-7. 517 Christensen AS, Hædersdal S, Storgaard H, Rose K, Hansen NL, Holst 518 9. JJ, et al. GIP and GLP-1 Potentiate Sulfonylurea-Induced Insulin Secretion in 519 Hepatocyte Nuclear Factor 1a Mutation Carriers. Diabetes. 2020;69(9):1989-520 2002. 521 Aaboe K, Knop FK, Vilsboll T, Volund A, Simonsen U, Deacon CF, et al. 522 10. 523 KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. 524 J Clin Endocrinol Metab. 2009;94(2):603-8. 525 Cordiner RLM, Mari A, Tura A, Pearson ER. The Impact of Low-dose 526 11. Gliclazide on the Incretin Effect and Indices of Beta-cell Function. J Clin 527 Endocrinol Metab. 2021;106(7):2036-46. 528 529 12. Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, et al. Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on 530 Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in 531 Patients with Type 2 Diabetes. 2006;91(11). 532 Ahren B, Pacini G, Foley JE, Schweizer A. Improved Meal-Related -533 13. Cell Function and Insulin Sensitivity by the Dipeptidyl Peptidase-IV Inhibitor 534 Vildagliptin in Metformin-Treated Patients With Type 2 Diabetes Over 1Year. 535 536 Diabetes Care. 2005;28(8):1936-40. 14. Bates D MM, Bolker B, Walker S "Fitting Linear Mixed-Effects Models" 537 Using LME4". Journal of Statistical Software. 2015;67(1):1 - 48. 538 SN W. Fast stable restricted maximum likelihood and marginal 539 15. 540 likelihood estimation of semiparametric generalized linear models. Journal of Royal Statistical Society (B). 2011;73(1):3 - 36. 541

542 16. Mari A, Ferrannini E. Beta-cell function assessment from modelling of 543 oral tests: an effective approach. Diabetes Obes Metab. 2008;10 Suppl 4:77-544 87. 17. Mari A, Pacini G, Murphy E, Ludvik B, Nolan JJ. A Model-Based Method 545 for Assessing Insulin Sensitivity From the Oral Glucose Tolerance Test. 546 547 Diabetes Care. 2001;24(3):539-48. Mari A, Tura A, Gastaldelli A, Ferrannini E. Assessing insulin secretion 18. 548 by modeling in multiple-meal tests: role of potentiation. Diabetes. 2002;51 549 Suppl 1(Supplement 1):S221-6. 550 551 19. R Development Core Team. R: A language and environment for statistical computing. 4.1.1 ed. Vienna, Austria: R Foundation for Statistical 552 Computing; 2010. 553 Mari A, Gastaldelli A, Foley JE, Pratley RE, Ferrannini E. Beta-cell 554 20. 555 function in mild type 2 diabetic patients: effects of 6-month glucose lowering with nateglinide. Diabetes Care. 2005;28(5):1132-8. 556 21. Glucose Concentrations of Less Than 3.0 mmol/L (54 mg/dL) Should 557 Be Reported in Clinical Trials: A Joint Position Statement of the American 558 559 Diabetes Association and the European Association for the Study of Diabetes. 560 Diabetes Care. 2017;40(1):155-7. Gonzalez D PM, Johnson J. PharmGKB: Very Important Pharmacogene 561 22. KCNJ11 PharmGKB2020 [Available from: 562 563 https://www.pharmgkb.org/vip/PA166169501. 23. Dennis JM, Henley WE, Weedon MN, Lonergan M, Rodgers LR, Jones 564 AG, et al. Sex and BMI Alter the Benefits and Risks of Sulfonylureas and 565 566 Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating 567 Stratification Using Routine Clinical and Individual Trial Data. Diabetes Care. 568 2018;41(9):1844-53. Salvo F, Moore N, Arnaud M, Robinson P, Raschi E, De Ponti F, et al. 569 24. Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of 570 571 hypoglycaemia: systematic review and meta-analysis. BMJ. 2016:i2231. 572 25. Proks P, De Wet H, Ashcroft FM. Molecular Mechanism of Sulphonylurea Block of KATP Channels Carrying Mutations That Impair ATP 573 574 Inhibition and Cause Neonatal Diabetes. Diabetes. 2013;62(11):3909-19. 575 26. Patane G, Piro S, Anello M, Rabuazzo AM, Vigneri R, Purrello F. Exposure to glibenclamide increases rat beta cells sensitivity to glucose. Br J 576 Pharmacol. 2000;129(5):887-92. 577 Dachicourt N, Bailbe D, Gangnerau MN, Serradas P, Ravel D, Portha B. 578 27. Effect of gliclazide treatment on insulin secretion and beta-cell mass in non-579 insulin dependent diabetic Goto-Kakisaki rats. Eur J Pharmacol. 1998;361(2-580 3):243-51. 581 582 28. van Haeften TW, Veneman TF, Gerich JE, van der Veen EA. Influence 583 of gliclazide on glucose-stimulated insulin release in man. Metabolism. 1991;40(7):751-5. 584 Davis TM, Daly F, Walsh JP, llett KF, Beilby JP, Dusci LJ, et al. 585 29. Pharmacokinetics and pharmacodynamics of gliclazide in Caucasians and 586

587 Australian Aborigines with type 2 diabetes. Br J Clin Pharmacol.

588 2000;49(3):223-30.

30. Zammitt NN, Frier BM. Hypoglycemia in Type 2 Diabetes:

590 Pathophysiology, frequency, and effects of different treatment modalities.

- 591 Diabetes Care. 2005;28(12):2948-61.
- 31. Zhang H, Liu X, Kuang H, Yi R, Xing H. Association of sulfonylurea

receptor 1 genotype with therapeutic response to gliclazide in type 2 diabetes.
 Diabetes Research and Clinical Practice. 2007;77(1):58-61.

- 595 32. Rastegari A, Rabbani M, Sadeghi HM, Imani ÉF, Hasanzadeh A,
- 596 Moazen F. Pharmacogenetic association of KCNJ11 (E23K) variant with
- <sup>597</sup> therapeutic response to sulphonylurea (glibenclamide) in Iranian patients.
- <sup>598</sup> International Journal of Diabetes in Developing Countries. 2015;35(4):630-1.
- 33. Viberti G, Kahn SE, Greene DA, Herman WH, Zinman B, Holman RR,
- 600 et al. A diabetes outcome progression trial (ADOPT): an international
- 601 multicenter study of the comparative efficacy of rosiglitazone, glyburide, and
- metformin in recently diagnosed type 2 diabetes. Diabetes Care.
- 603 2002;25(10):1737-43.
- 34. Komajda M, Curtis P, Hanefeld M, Beck-Nielsen H, Pocock SJ,
- <sup>605</sup> Zambanini A, et al. Effect of the addition of rosiglitazone to metformin or
- sulfonylureas versus metformin/sulfonylurea combination therapy on
- ambulatory blood pressure in people with type 2 diabetes: a randomized
- controlled trial (the RECORD study). Cardiovasc Diabetol. 2008;7:10.
- 35. Faerch K, Torekov SS, Vistisen D, Johansen NB, Witte DR, Jonsson A,
- et al. GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-
- 611 Detected Type 2 Diabetes, and Obesity and Influenced by Sex: The
- 612 ADDITION-PRO Study. Diabetes. 2015;64(7):2513-25.



Figure 1: Unblinded randomised crossover study design involving four different study intervention periods, each 14 days duration. Participants completed a 2-hour mixed meal tolerance test at the end of each study period.



Figure 2: a) Glucose sensitivity b) Insulin Secretion at 8mmol/I glucose c) Rate Sensitivity d) Potentiation Factor by treatment (Mean (SEM))



Figure 3: Dose response by treatment (Mean (SEM))



Figure 4: Mean (SEM) a) Fasting Glucose b) Glucose from Mixed Meal Test

а



Figure 5: Dose response to treatment by KCNJ11 E23K genotype (Mean (SEM))



Figure 6: Gender Differences in Treatment Response (Mean (SEM)) a) Glucose from Mixed Meal Test b) Glucose Sensitivity c) Insulin Secretion at 8mmol/L Glucose